# ERC1671 to Treat Malignant Gliomas When Given in Combination With GM-CSF, Cyclophosphamide, Bevacizumab and Pembrolizumab

> **NCT05366062** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Epitopoietic Research Corporation** · enrollment: 28 (estimated)

## Conditions studied

- Glioma, Malignant

## Interventions

- **DRUG:** ERC1671
- **DRUG:** GM-CSF
- **DRUG:** Cyclophosphamide
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT05366062
- **Lead sponsor:** Epitopoietic Research Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2022-07-01
- **Primary completion:** 2025-07-31
- **Final completion:** 2026-07-31
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2022-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05366062

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05366062, "ERC1671 to Treat Malignant Gliomas When Given in Combination With GM-CSF, Cyclophosphamide, Bevacizumab and Pembrolizumab". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05366062. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*